Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you

recruiting
3 977
countries
28
conditions
2 105

14 trials match your criteria

Glucose tolerance impaired+1

Recruiting

Study of pioglitazone and metformin combination treatment for patients with Metabolic Associated Fatty Liver Disease and prediabetes

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pioglitazone

Chronic myeloid leukaemia

Recruiting

Study of Pioglitazone and Avelumab Combined with Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients with Complete Cytogenetic Response

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab

Type 2 diabetes mellitus+1

Recruiting

Study on the Effects of Empagliflozin, Pioglitazone, and Semaglutide for Patients with Type 2 Diabetes

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Empagliflozin

Anti-neutrophil cytoplasmic antibody positive vasculitis

Recruiting

Study on Pioglitazone for Improving Kidney Health in Patients with ANCA-Associated Vasculitis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dexchlorpheniramine

Vitiligo

Not yet recruiting

A study testing pioglitazone for adults with non-segmental vitiligo to see if it works and is safe when used with light therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Pioglitazone

Type 2 diabetes mellitus

Not yet recruiting

Study on Switching from Dulaglutide to Tirzepatide for Adults with Type 2 Diabetes

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bromocriptine

Vitiligo

Not yet recruiting

Study on Pioglitazone for Adults with Non-Segmental Vitiligo

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Pioglitazone

Type 2 diabetes mellitus

Not recruiting

Study on the Effectiveness of Weekly IcoSema (Insulin Icodec and Semaglutide) vs. Daily Insulin Glargine for Adults with Type 2 Diabetes Not Controlled by Oral Drugs

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin

Type 2 diabetes mellitus

Not recruiting

Study on the Effects of Ertugliflozin and Semaglutide on Heart Health in Patients with Type 2 Diabetes

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Canagliflozin

Type 2 diabetes mellitus

Not recruiting

Study on Personalized Treatment Using Dapagliflozin, Dulaglutide, and Metformin for Patients with Uncontrolled Type 2 Diabetes

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Canagliflozin

Polycystic ovarian syndrome

Not recruiting

Study on the Effects of Spironolactone, Pioglitazone, and Metformin for Adolescent Girls and Young Women with Polycystic Ovary Syndrome (PCOS)

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Metformin

Type 2 diabetes mellitus

Not recruiting

Study on the Effectiveness and Safety of Adding Pioglitazone to Metformin and Empagliflozin for Patients with Type 2 Diabetes with Poor Blood Sugar Control

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Empagliflozin

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.